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patients
Cingarlini, Sara1 Genestreti, Giovenzio2 Terzi, Alberto3 Bonomi, Maria1 
Fogazzi, Gianluca1 Ravaioli, Alberto4 Papi, Maximiliam5 Molino, 
Annamaria1 Cetto, Gianluigi1 Santo, Antonio1 
1 Department of Medical Oncology, University of Verona, Verona, Italy 2 
Division of Oncology, Ospedale Morgagni, Forlì, Rimini, Italy 3 Section 
of Thoracic Surgery, Azienda Ospedaliera di Verona, Verona, Italy 4 
Section of Oncology and Hematology, Ospedale di Cattolica-Rimini, 
Rimini, Italy 5 Section of Oncohematology, Ospedale di Rimini-Cat-
tolica, Rimini, Italy 
Introduction: MPM is a rare neoplasia but with an increasing 
incidence. It is primarly associated with asbestos exposure and it is 
characterized by a poor prognosis both due to its aggressiveness and to 
the lack of effective effective treatments. Surgery plays a pivotal role in 
the treatment of the early stage disease; the role of chemotherapy (CT) 
and local radiation (RT) is controversial both in the adjuvant and ad-
vanced setting. Recent availability of more effective drugs has allowed 
a renewed interest in medical therapy of this disease.
Patients and methods: We analyzed 91 cases of MPM collected by 
the Department of Thoracic Surgery of Civic Hospital of Verona and by 
Medical Oncology of the Hospital of Verona and Rimini from 1983 to 
2005.
We considered 3 groups of pts: pts with early MPM treated only with 
surgery (49 pts); pts treated with surgery plus adjuvant CT/RT(11 pts) 
and pts with advanced MPM treated only with CT(31 pts).
Results: The characteristics of pts were: median age 62 years; M/F 
73/18; histology: 66 epithelial, 17 biphasic, 4 sarcomatous and 4 undif-
ferentiated; 55 Stage I-II, 36 III-IV according to Brigham’s stadiation. 
60 pts with good PS (ECOG 0-1) underwent pleuropneumonectomy; 
49 pts underwent only radical surgery, with macroscopic residual of 
disease in 4 pts; 9 pts had adjuvant CT-RT, 2 adjuvant RT and 31 pal-
liative CT.
Operative mortality was 7.5 %; surgical accidents occurred in 39% of 
pts.
In adjuvant setting 3 pts were treated with CAP schedule (CTX 600 
mg/m2; ADM 50 mg/m2; CDDP 70 mg/m2) and 6 pts with CBDCA 
(AUC 6) and TXL (200 mg/m2) followed by RT (50 Gy); 
31 pts were treated with palliative CT. 26 patients underwent CT with 
CBDCA (AUC 5) or CDDP (80 mg/m2) and Pemetrexed 500 mg/m2; 5 
patients underwent CT with CDDP (80 mg/m2) and Gemcitabine (1000 
mg/m2). 
OS at 1, 3 and 5 years for pts treated only with surgery was respectively 
49%, 23 and 14%; OS at 1, 3 and 5 years for epithelial subtype was 
61%, 30 and 18%; for biphasic and sarcomatous histotype it was 8% at 
1 year, 0% at 3 years. 
Median Survival for pts treated with adjuvant CT + RT was 22 months.
In the group of patients treated with CT for advanced disease we 
observed an overall response rate of 19% and an overall survival of 9.5 
months. 
Conclusions: In our experience surgery, preferably associated with 
multimodality adjuvant strategy including CT/RT, maintains a pivotal 
role in the treatment of early MPM; the association of CBDCA and 
TXL in adjuvant setting seems to be better tolerated than CAP despite 
the need of further studies including new CT regimens. Prognosis of pts 
with advanced MPM or relapsed after surgery remains very poor espe-
cially for non epithelioid histotypes. New chemotherapeutic regimens 
including pemetrexed are better tolerated and more effective than older 
ones also in the advanced disease.
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Primary endobronchial and pulmonary mucosa-associated 
lymphoid tissue (MALT) lymphoma; clinical manifestation and 
radiographic features
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Primary endobronchial and pulmonary malignant lymphoma constitute 
0.4% of all lymphomas. MALT lymphoma is characterized by nonin-
vasive lymphoplasmacytic inﬁltration where foci of follicle center cells 
invade the epithelial structures, forming the lymphoepithelial lesion. 
Immunohistological examination often shows that neoplastic cells have 
the characteristic B-cell lymphoma. We experienced 5 cases of MALT 
lymphoma. Case 1: A 62-year-old woman was admitted because of 
chest abnormal shadow. Chest X-ray revealed atelectasis in the right 
upper lobe. A bronchoscopy showed an elevated lesion at the oriﬁce of 
right B3. Histological examination showed MALT lymphoma. Case 2: 
A 74-year-old woman was pointed extrinsic compression of the esopha-
gus at upper gastrointestinal endoscope. A bronchoscopy revealed tra-
cheal mass in the left of the trachea. Case 3: A 48-year-old woman had 
been suffering from shortness of breath, fever and general fatigue. She 
was diagnosed pulmonary MALT lymphoma ﬁve years ago. Chest ra-
diography showed pneumothorax of the left lung. Case 4 (Fig. left): A 
88-year-old man was pointed out a mass shadow of the left lower lobe 
on chest CT for following thoracic aortic aneurysm. Bronchoscopy was 
performed and transbronchial tumor biopsy was diagnosed as pseudo-
lymphoma at that time. Although tumor increased in size nine months 
later, re-biopsy was performed and diagnosed MALT lymphoma.Case 
5 (Fig. right): A 57-year-old woman was pointed out chest radiograph 
abnormality and chest computed tomography showed consolidation 
shadow at right middle lobe. We will show clinical manifestation and 
radiographic ﬁndings of our ﬁve cases and review of the literature.
